AstraZeneca Caps Inhaler Costs at $35 to Aid Vulnerable Patients
AstraZeneca has reduced monthly inhaler costs to $35, aiming to help vulnerable asthma and chronic obstructive pulmonary disease..
HNGN
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
AstraZeneca has reduced monthly inhaler costs to $35, aiming to help vulnerable asthma and chronic obstructive pulmonary disease..